Wellington Management Group LLP Has $1.54 Million Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Wellington Management Group LLP lessened its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 45.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 191,329 shares of the biopharmaceutical company's stock after selling 159,258 shares during the quarter. Wellington Management Group LLP owned about 0.39% of Theravance Biopharma worth $1,542,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TBPH. Quantbot Technologies LP acquired a new position in Theravance Biopharma during the third quarter worth $60,000. China Universal Asset Management Co. Ltd. lifted its position in Theravance Biopharma by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 3,696 shares during the period. Ballentine Partners LLC purchased a new position in Theravance Biopharma in the third quarter worth $104,000. Hsbc Holdings PLC acquired a new position in Theravance Biopharma during the second quarter worth $108,000. Finally, XTX Topco Ltd acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $129,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares of the company's stock, valued at $2,904,687. This trade represents a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Theravance Biopharma presently has a consensus rating of "Hold" and an average target price of $13.75.

Theravance Biopharma Trading Up 0.2 %

NASDAQ TBPH traded up $0.02 on Thursday, reaching $9.73. The stock had a trading volume of 241,773 shares, compared to its average volume of 333,978. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71. The business has a 50 day moving average price of $9.16 and a 200 day moving average price of $8.80. The company has a market capitalization of $478.46 million, a price-to-earnings ratio of -9.63 and a beta of 0.23.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The firm had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the prior year, the firm earned ($0.17) EPS. On average, analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.